GSK, Siena, Italy.
Host Pathogen Interactions Group, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland.
Front Immunol. 2021 Jul 7;12:705360. doi: 10.3389/fimmu.2021.705360. eCollection 2021.
is one of the most important human pathogens worldwide. Its high antibiotic resistance profile reinforces the need for new interventions like vaccines in addition to new antibiotics. Vaccine development efforts against have failed so far however, the findings from these human clinical and non-clinical studies provide potential insight for such failures. Currently, research is focusing on identifying novel vaccine formulations able to elicit potent humoral and cellular immune responses. Translational science studies are attempting to discover correlates of protection using animal models as well as and models assessing efficacy of vaccine candidates. Several new vaccine candidates are being tested in human clinical trials in a variety of target populations. In addition to vaccines, bacteriophages, monoclonal antibodies, centyrins and new classes of antibiotics are being developed. Some of these have been tested in humans with encouraging results. The complexity of the diseases and the range of the target populations affected by this pathogen will require a multipronged approach using different interventions, which will be discussed in this review.
是全球最重要的人类病原体之一。其高度的抗生素耐药性特征,除了需要新的抗生素外,还需要新的干预措施,如疫苗。然而,迄今为止针对 的疫苗开发工作都失败了,这些人体临床和非临床研究的结果为这些失败提供了潜在的见解。目前,研究的重点是确定能够引发强大体液和细胞免疫反应的新型疫苗制剂。转化科学研究正在使用动物模型以及 和 模型来探索保护相关性,以评估候选疫苗的功效。几种新的疫苗候选物正在各种目标人群的人体临床试验中进行测试。除了疫苗,噬菌体、单克隆抗体、Centyrins 和新类别的抗生素也在开发中。其中一些已经在人体中进行了测试,结果令人鼓舞。该病原体所影响的疾病的复杂性和目标人群的范围,将需要使用不同的干预措施,采取多管齐下的方法,这将在本文中进行讨论。
Microbiol Res. 2023-6
Microorganisms. 2025-8-4
Clin Exp Vaccine Res. 2025-7
Microb Cell. 2020-10-5
JCI Insight. 2020-10-2
Nature. 2020-8-12
N Engl J Med. 2020-7-14